Guoxian Wei1, Na Tian1, Adriana C Valery1, Yi Zhong1, Detlef Schuppan2, Eva J Helmerhorst1. 1. Department of Molecular and Cell Biology, Henry M. Goldman School of Dental Medicine, Boston, Massachusetts, USA. 2. 1] Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA [2] Institute of Translational Immunology and Research Center for Immunology (FZI), University Medical Center, Johannes-Gutenberg-University, Mainz, Germany.
Abstract
OBJECTIVES: Immunogenic gluten proteins implicated in celiac disease (CD) largely resist degradation by human digestive enzymes. Here we pursued the isolation of gluten-degrading organisms from human feces, aiming at bacteria that would digest gluten under acidic conditions, as prevails in the stomach. METHODS: Bacteria with gluten-degrading activities were isolated using selective gluten agar plates at pH 4.0 and 7.0. Proteins in concentrated bacterial cell sonicates were separated by diethylaminoethanol chromatography. Enzyme activity was monitored with chromogenic substrates and gliadin zymography. Elimination of major immunogenic gluten epitopes was studied with R5 and G12 enzyme-linked immunosorbent assays. RESULTS: Gliadin-degrading enzyme activities were observed for 43 fecal isolates, displaying activities in the ~150-200 and <50 kDa regions. The active strains were identified as Pseudomonas aeruginosa. Gliadin degradation in gel was observed from pH 2.0 to 7.0. Liquid chromatography-electrospray ionization-tandem mass spectrometry analysis identified the enzyme as pseudolysin (lasB), a metalloprotease belonging to the thermolysin (M4) family proteases. Its electrophoretic mobility in SDS-polyacrylamide gel electrophoresis and gliadin zymogram gels was similar to that of a commercial lasB preparation, with tendency of oligomerization. Pseudolysin eliminated epitopes recognized by the R5 antibody, while those detected by the G12 antibody remained intact, despite destruction of the nearby major T-cell epitope QPQLPY. CONCLUSIONS: Pseudolysin was identified as an enzyme cleaving gluten effectively at extremely low as well as near-neutral pH values. The potential to degrade gluten during gastric transport opens possibilities for its application as a novel therapeutic agent for the treatment of CD.
OBJECTIVES: Immunogenic gluten proteins implicated in celiac disease (CD) largely resist degradation by human digestive enzymes. Here we pursued the isolation of gluten-degrading organisms from human feces, aiming at bacteria that would digest gluten under acidic conditions, as prevails in the stomach. METHODS: Bacteria with gluten-degrading activities were isolated using selective gluten agar plates at pH 4.0 and 7.0. Proteins in concentrated bacterial cell sonicates were separated by diethylaminoethanol chromatography. Enzyme activity was monitored with chromogenic substrates and gliadin zymography. Elimination of major immunogenic gluten epitopes was studied with R5 and G12 enzyme-linked immunosorbent assays. RESULTS: Gliadin-degrading enzyme activities were observed for 43 fecal isolates, displaying activities in the ~150-200 and <50 kDa regions. The active strains were identified as Pseudomonas aeruginosa. Gliadin degradation in gel was observed from pH 2.0 to 7.0. Liquid chromatography-electrospray ionization-tandem mass spectrometry analysis identified the enzyme as pseudolysin (lasB), a metalloprotease belonging to the thermolysin (M4) family proteases. Its electrophoretic mobility in SDS-polyacrylamide gel electrophoresis and gliadin zymogram gels was similar to that of a commercial lasB preparation, with tendency of oligomerization. Pseudolysin eliminated epitopes recognized by the R5 antibody, while those detected by the G12 antibody remained intact, despite destruction of the nearby major T-cell epitope QPQLPY. CONCLUSIONS: Pseudolysin was identified as an enzyme cleaving gluten effectively at extremely low as well as near-neutral pH values. The potential to degrade gluten during gastric transport opens possibilities for its application as a novel therapeutic agent for the treatment of CD.
Authors: Jonathan Gass; Harmit Vora; Michael T Bethune; Gary M Gray; Chaitan Khosla Journal: J Pharmacol Exp Ther Date: 2006-06-06 Impact factor: 4.030
Authors: Greetje J Tack; Jolanda M W van de Water; Maaike J Bruins; Engelina M C Kooy-Winkelaar; Jeroen van Bergen; Petra Bonnet; Anita C E Vreugdenhil; Ilma Korponay-Szabo; Luppo Edens; B Mary E von Blomberg; Marco W J Schreurs; Chris J Mulder; Frits Koning Journal: World J Gastroenterol Date: 2013-09-21 Impact factor: 5.742
Authors: Lu Shan; Shuo-Wang Qiao; Helene Arentz-Hansen; Øyvind Molberg; Gary M Gray; Ludvig M Sollid; Chaitan Khosla Journal: J Proteome Res Date: 2005 Sep-Oct Impact factor: 4.466
Authors: M Thuong; K Arvaniti; R Ruimy; P de la Salmonière; A Scanvic-Hameg; J C Lucet; B Régnier Journal: J Hosp Infect Date: 2003-04 Impact factor: 3.926
Authors: Anna Sapone; Julio C Bai; Carolina Ciacci; Jernej Dolinsek; Peter H R Green; Marios Hadjivassiliou; Katri Kaukinen; Kamran Rostami; David S Sanders; Michael Schumann; Reiner Ullrich; Danilo Villalta; Umberto Volta; Carlo Catassi; Alessio Fasano Journal: BMC Med Date: 2012-02-07 Impact factor: 8.775
Authors: Ludvig M Sollid; Shuo-Wang Qiao; Robert P Anderson; Carmen Gianfrani; Frits Koning Journal: Immunogenetics Date: 2012-02-10 Impact factor: 2.846
Authors: Jose F Garcia-Mazcorro; Xaira Rivera-Gutierrez; Orestes De Jesus Cobos-Quevedo; Peter Grube-Pagola; Arturo Meixueiro-Daza; Karina Hernandez-Flores; Francisco J Cabrera-Jorge; Hector Vivanco-Cid; Scot E Dowd; Jose M Remes-Troche Journal: Nutrients Date: 2018-11-02 Impact factor: 5.717